Ranibizumab in retinal vein occlusion: Treatment recommendations by an expert panel

British Journal of Ophthalmology

Volumn 99, Issue 3, 2015, Pages 297-304

  Gerding, Heinrich ^a,b   Monés, Jordi ^c   Tadayoni, Ramin ^d   Boscia, Francesco ^e   Pearce, Ian ^f   Priglinger, Siegfried ^g  

^a Klinik Pallas   (Switzerland)

^b UNIVERSITY OF MÜNSTER   (Germany)

^c CENTRO MÉDICO TEKNON   (Spain)

^d HÔPITAL LARIBOISIÈRE   (France)

^e UNIVERSITY OF SASSARI   (Italy)

^f ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^g KEPLER UNIVERSITY HOSPITAL   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ACUTE HEART INFARCTION; ANGINA PECTORIS; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRANCH RETINAL VEIN OCCLUSION; CENTRAL FOVEAL THICKNESS; CENTRAL RETINA VEIN OCCLUSION; CENTRAL RETINAL THICKNESS; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOPHTHALMITIS; EYE EDEMA; FLUORESCENCE ANGIOGRAPHY; HEART INFARCTION; HEMIRETINAL VEIN OCCLUSION; HUMAN; HYPERTENSION; INTESTINE PERFORATION; INTRAOCULAR HEMORRHAGE; ISCHEMIA; LASER COAGULATION; MACULAR EDEMA; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA FOVEA; RETINA VEIN OCCLUSION; THERAPY DELAY; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; VISUAL ACUITY; VISUAL IMPAIRMENT; ANTAGONISTS AND INHIBITORS; EXPERT WITNESS; INTRAVITREAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; RETINAL VEIN OCCLUSION; VISION DISORDERS;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; EXPERT TESTIMONY; HUMANS; INTRAVITREAL INJECTIONS; PRACTICE GUIDELINES AS TOPIC; RANIBIZUMAB; RETINAL VEIN OCCLUSION; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISION DISORDERS;

EID: 84923225018     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2014-305041     Document Type: Article

References (59)

1. Argon Laser Photocoagulation for Macular Edema in Branch Vein Occlusion. The Branch Vein Occlusion Study Group. Am J Ophthalmol 1984;98:271-82.
2. Baseline and Early Natural History Report. The Central Vein Occlusion Study. Arch Ophthalmol 1993;111:1087-95.
3. Shahid H, Hossain P, Amoaku WM. The management of retinal vein occlusion: is interventional ophthalmology the way forward? Br J Ophthalmol 2006;90:627-39.
4. Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesis and management. J Thromb Haemost 2010;8:1886-94.
5. Awdeh RM, Elsing SH, Deramo VA, et al. Vision-related quality of life in persons with unilateral branch retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Br J Ophthalmol 2010;94:319-23.
6. Deramo VA, Cox TA, Syed AB, et al . Vision-related quality of life in people with central retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol 2003;121:1297-302.
7. Evaluation of Grid Pattern Photocoagulation for Macular Edema in Central Vein Occlusion. The Central Vein Occlusion Study Group M report. Ophthalmology 1995;102:1425-33.
8. Scott IU, Ip MS, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 6. Arch Ophthalmol 2009;127:1115-28.
9. Ip MS, Scott IU, VanVeldhuisen PC, et al. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009;127:1101-14.
10. Haller JA, Bandello F, Belfort R Jr., et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011;118:2453-60.
11. Genentech. FDA Approves Lucentis® (Ranibizumab Injection) for the Treatment of Macular Edema Following Retinal Vein Occlusion. 2010. http://www.gene.com/ media/press-releases/12827/2010-06-22/fda-approves-lucentis-ranibizumab-inject (accessed 13 May 2014)
12. Novartis Europharm Limited. Lucentis® (ranibizumab) Summary of Product Characteristics. 2014. http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Product-Information/human/000715/WC500043546.pdf (accessed 12 May 2014)
13. Genentech Inc. Lucentis® (ranibizumab) Prescribing Information. 2013. http://www.gene.com/gene/products/information/pdf/lucentis-prescribing.pdf (accessed 1 Feb 2013)
14. Novartis. Novartis gains new indication for Lucentis ® in EU for vision loss due to Diabetic Macular Edema, a leading cause of blindness. 2011. http://www.novartis.com/newsroom/media-releases/en/2011/1477848.shtml (accessed 12 May 2014)
15. The Royal College of Ophthalmologists. Interim guidelines for management of retinal vein occlusion. London: The Royal College of Ophthalmologists, 2010. http://www.rcophth.ac.uk/core/core-picker/download.asp?id=728&filetitle=Interim+Guidelines+for+Management+of+Retinal+Vein+Occlusion+2010 (accessed 12 May 2014).
16. Coscas G, Loewenstein A, Augustin A, et al. Management of retinal vein occlusion-consensus document. Ophthalmologica 2011;226:4-28.
17. Deutsche Ophthalmologische Gesellschaft. Stellungnahme der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbandes der Augenärzte Deutschlands zur Therapie des Makulaödems beim retinalen Venenverschluss: Therapeutische Strategien. Ophthalmologica 2012;109:818-31.
18. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-13.
19. Karia N. Retinal vein occlusion: pathophysiology and treatment options. Clin Ophthalmol 2010;4:809-16.
20. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994;331:1480-7.
21. Noma H, Funatsu H, Yamasaki M, et al. Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6. Am J Ophthalmol 2005;140:256-61.
22. Noma H, Minamoto A, Funatsu H, et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2006;244:309-15.
23. Noma H, Funatsu H, Yamasaki M, et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular oedema in branch retinal vein occlusion. Eye (Lond) 2008;22:42-8.
24. Noma H, Funatsu H, Mimura T, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in macular edema with central retinal vein occlusion. Curr Eye Res 2011;36:256-63.
25. Kwong TQ, Mohamed M. Anti vascular endothelial growth factor therapies in ophthalmology: current use, controversies and the future. Br J Clin Pharmacol 2014; doi: 10.1111/bcp.12371.
26. NICE. Ranibizumab for treating choroidal neovascularisation associated with pathological myopia. 2013.
27. Bayer HealthCare. Eyelea® (aflibercept) Summary of Product Characteristics. 2014.
28. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-908.
29. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-411.
30. Krebs I, Schmetterer L, Boltz A, et al. A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration. Br J Ophthalmol 2013;97:266-71.
31. Kodjikian L, Souied EH, Mimoun G, et al. Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology 2013;120:2300-9.
32. Beutel J, Ziemssen F, Luke M, et al. Intravitreal bevacizumab treatment of macular edema in central retinal vein occlusion: one-year results. Int Ophthalmol 2010;30:15-22.
33. Ferrara DC, Koizumi H, Spaide RF. Early bevacizumab treatment of central retinal vein occlusion. Am J Ophthalmol 2007;144:864-71.
34. Figueroa MS, Contreras I, Noval S, et al. Results of bevacizumab as the primary treatment for retinal vein occlusions. Br J Ophthalmol 2010;94:1052-6.
35. Hoeh AE, Ach T, Schaal KB, et al. Long-term follow-up of OCT-guided bevacizumab treatment of macular edema due to retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2009;247:1635-41.
36. Prager F, Michels S, Kriechbaum K, et al. Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial. Br J Ophthalmol 2009;93:452-6.
37. Yuan A, Ahmad BU, Xu D, et al. Comparison of intravitreal ranibizumab and bevacizumab for the treatment of macular edema secondary to retinal vein occlusion. Int J Ophthalmol 2014;7:86-91.
38. ClinicalTrials.gov. NCT01969708. 2013.
39. Wroblewski JJ, Wells JA III, Adamis AP, et al. Pegaptanib sodium for macular edema secondary to central retinal vein occlusion. Arch Ophthalmol 2009;127:374-80.
40. Heier JS, Clark WL, Boyer DS, et al. Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study. Ophthalmology 2014; doi: 10.1016/j.ophtha.2014.01.027.
41. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1102-12.
42. Brown DM, Campochiaro PA, Singh RP, et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1124-33.
43. Brown DM, Campochiaro PA, Bhisitkul RB, et al. Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study. Ophthalmology 2011;118:1594-602.
44. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 2011;118:2041-9.
45. Heier JS, Campochiaro PA, Yau L, et al. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial. Ophthalmology 2012;119:802-9.
46. Kinge B, Stordahl PB, Forsaa V, et al. Efficacy of ranibizumab in patients with macular edema secondary to central retinal vein occlusion: results from the sham-controlled ROCC study. Am J Ophthalmol 2010;150:310-4.
47. Risard SM, Pieramici DJ, Rabena MD, et al . Intravitreal ranibizumab for macular edema secondary to central retinal vein occlusion. Retina 2011;31: 1060-7.
48. Campochiaro PA, Hafiz G, Channa R, et al. Antagonism of vascular endothelial growth factor for macular edema caused by retinal vein occlusions: two-year outcomes. Ophthalmology 2010;117:2387-94.
49. Spaide RF, Chang LK, Klancnik JM, et al. Prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Am J Ophthalmol 2009;147:298-306.
50. Campochiaro PA, Hafiz G, Shah SM, et al. Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 2008;16:791-9.
51. Alfaro DV III, Jablon EP, Kerrison JB, et al. Ranibizumab for the treatment of branch retinal vein occlusion-associated cystoid macular edema [abstract]. Invest Ophthalmol Vis Sci 2008;49:2699.
52. Pieramici DJ, Rabena M, Castellarin AA, et al. Ranibizumab for the treatment of macular edema associated with perfused central retinal vein occlusions. Ophthalmology 2008;115:e47-54.
53. Wykrota H, Trzciakowski K, Gierek-Lapinska A. Ranibizumab treatment of macular edema secondary to retinal vein occlusion [abstract]. 8th EURETINA Congress, 22-25 May 2008.
54. Campochiaro PA, Johnson MW, Arevalo JF, et al. Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology 2013;120:795-802.
55. Arvas S, Ocakoglu O, Ozkan S. The capillary blood flow in ischaemic type central retinal vein occlusion: the effect of laser photocoagulation. Acta Ophthalmol Scand 2002;80:490-4.
56. Servais GE, Thompson HS, Hayreh SS. Relative afferent pupillary defect in central retinal vein occlusion. Ophthalmology 1986;93:301-3.
57. Rogers SL, McIntosh RL, Lim L, et al. Natural history of branch retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2010;117:1094-101.
58. Pearce I, Gerding H, Mitchell P, et al. Evaluation of individual patient ranibizumab treatment based on a visual acuity stability concept in retinal vein occlusion patients [abstract]. American Academy of Ophthalmology 2011:PO547.
59. Shah AM, Bressler NM, Jampol LM. Does laser still have a role in the management of retinal vascular and neovascular diseases? Am J Ophthalmol 2011;152:332-9.